Recent data from the HIV-CAUSAL Collaboration suggest that immediate and delayed ART initiation result in similar rates of acquired drug resistance. In HIV-positive individuals receiving routine clinical care in Europe, the estimated 7-year risk for clinically identified acquired drug resistance was approximately 3% under all ART initiation strategies.
When ART initiation is deferred, consideration of repeat drug resistance testing shortly before treatment initiation is recommended to ensure the patient has not acquired drug-resistant virus (ie, HIV superinfection).
Learn more about HIV testing and treatment initiation.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michael Stuart Bronze. Fast Five Quiz: Treatment-Resistant HIV - Medscape - May 10, 2021.